E. Stadtmauer

845 total citations
16 papers, 365 citations indexed

About

E. Stadtmauer is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, E. Stadtmauer has authored 16 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 8 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in E. Stadtmauer's work include Multiple Myeloma Research and Treatments (5 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Acute Myeloid Leukemia Research (3 papers). E. Stadtmauer is often cited by papers focused on Multiple Myeloma Research and Treatments (5 papers), Hematopoietic Stem Cell Transplantation (4 papers) and Acute Myeloid Leukemia Research (3 papers). E. Stadtmauer collaborates with scholars based in United States, Netherlands and Canada. E. Stadtmauer's co-authors include Jesús F. San Miguel, Mario Boccadoro, Donna Reece, Pieter Sonneveld, Paul G. Richardson, David Irwin, Sagar Lonial, Anthony Boral, Dina Ben‐Yehuda and James D. Cavenagh and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Annals of the New York Academy of Sciences.

In The Last Decade

E. Stadtmauer

16 papers receiving 352 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Stadtmauer United States	8	271	184	168	55	42	16	365
MQ Lacy United States	11	408 1.5×	347 1.9×	229 1.4×	81 1.5×	36 0.9×	11	517
Hannah Hunter United Kingdom	8	312 1.2×	202 1.1×	160 1.0×	85 1.5×	33 0.8×	21	397
T‐T. Pelliniemi Finland	8	212 0.8×	124 0.7×	129 0.8×	59 1.1×	83 2.0×	11	368
Yaozhong Zhao China	10	219 0.8×	152 0.8×	146 0.9×	57 1.0×	26 0.6×	20	314
Xenofon Papanikolaou United States	7	241 0.9×	167 0.9×	150 0.9×	50 0.9×	13 0.3×	30	310
Gaku Oshikawa Japan	10	169 0.6×	152 0.8×	82 0.5×	79 1.4×	26 0.6×	29	326
M Fogli Italy	9	245 0.9×	87 0.5×	112 0.7×	44 0.8×	124 3.0×	17	344
Michelle E. Maglio United States	8	215 0.8×	188 1.0×	149 0.9×	33 0.6×	18 0.4×	9	359
Bonnie Jenkins United States	9	415 1.5×	326 1.8×	247 1.5×	43 0.8×	17 0.4×	10	459
H. L. Seewann Austria	11	208 0.8×	85 0.5×	102 0.6×	109 2.0×	33 0.8×	27	325

Countries citing papers authored by E. Stadtmauer

Since Specialization

Citations

This map shows the geographic impact of E. Stadtmauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Stadtmauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Stadtmauer more than expected).

Fields of papers citing papers by E. Stadtmauer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Stadtmauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Stadtmauer. The network helps show where E. Stadtmauer may publish in the future.

Co-authorship network of co-authors of E. Stadtmauer

This figure shows the co-authorship network connecting the top 25 collaborators of E. Stadtmauer. A scholar is included among the top collaborators of E. Stadtmauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Stadtmauer. E. Stadtmauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Costa, Luciano J., E. Stadtmauer, Faith E. Davies, et al.. (2019). PS1375 UPDATED SAFETY AND EFFICACY FROM A PHASE 2 STUDY OF VENETOCLAX PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere. 3(S1). 629–629. 2 indexed citations

Miguel, Jesús F. San, Paul G. Richardson, Pieter Sonneveld, et al.. (2008). Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia. 22(4). 842–849. 130 indexed citations

White, Darrell, et al.. (2006). Bortezomib is active in Waldenstrom’s Macroglobulinemia (WM)—Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM. Journal of Clinical Oncology. 24(18_suppl). 7543–7543. 5 indexed citations

Andreadis, Charalambos, Jakub Svoboda, Selina M. Luger, et al.. (2005). Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplantation. 36(11). 955–961. 19 indexed citations

Miguel, Jesús F. San, Paul G. Richardson, Pieter Sonneveld, et al.. (2005). Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.. Blood. 106(11). 366–366. 35 indexed citations

Lonial, Sagar, Paul G. Richardson, Pieter Sonneveld, et al.. (2005). Hematologic Profiles in the Phase 3 APEX Trial.. Blood. 106(11). 3474–3474. 13 indexed citations

Richardson, Paul G., Pieter Sonneveld, M. Schuster, et al.. (2004). Bortezomib Demonstrates Superior Efficacy to High-Dose Dexamethasone in Relapsed Multiple Myeloma: Final Report of the APEX Study.. Blood. 104(11). 1479–1479. 14 indexed citations

Vesole, David H., E. Stadtmauer, Lawrence T. Goodnough, et al.. (2004). Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation (SCT): results of the phase III sprint trial of intercept pathogen inactivated platelets. Biology of Blood and Marrow Transplantation. 10. 85–85. 3 indexed citations

Tsai, Donald E., Stephen J. Schuster, Alexander Matthies, et al.. (2000). Progressive Intermediate-Grade Non-Hodgkin's Lymphoma After High-Dose Therapy and Autologous Peripheral Stem-Cell Transplantation: Changing the Natural History with Monoclonal Antibody Therapy. Clinical Lymphoma. 1(1). 62–66. 5 indexed citations

10.

Visonneau, S, Alessandra Cesano, David Porter, et al.. (2000). Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.. PubMed. 6(5). 1744–54. 33 indexed citations

11.

Stadtmauer, E., et al.. (1996). Bone marrow purging with oligodeoxynucleotides.. Blood. 88(4). 1517–1517. 3 indexed citations

12.

Gewirtz, AM, S. M. Luger, & E. Stadtmauer. (1996). Bone marrow purging with oligodeoxynucleotides [letter; comment]. Blood. 88(4). 1517–1517. 12 indexed citations

13.

Biggs, David D., E. Stadtmauer, Patricia Mangan, et al.. (1994). 4-Hydroperoxycyclophosphamide purged autologous bone marrow transplantation of relapsed, responding non-Hodgkin's lymphoma with granulocyte colony stimulating factor support results in reliable hematopoietic recovery.. PubMed. 389. 9–15. 1 indexed citations

14.

Clevenger, Charles V., et al.. (1993). Detection of Bone Marrow Breast Carcinoma Metastasis Using Multiparameter Flow Cytometry. Annals of the New York Academy of Sciences. 677(1). 400–401. 7 indexed citations

15.

Cassileth, Peter A., Janet Andersen, Hillard M. Lazarus, et al.. (1993). Autologous bone marrow transplant in acute myeloid leukemia in first remission.. Journal of Clinical Oncology. 11(2). 314–319. 79 indexed citations

16.

Tierney, D. Kathryn, et al.. (1993). Autologous bone marrow transplantation. A review of the principles and complications.. PubMed. 16(3). 204–13. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact